Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome. 2013

Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
Department of Rheumatology and Internal Diseases, Pomeranian Medical University, Szczecin, Poland. hannapb@wp.pl

BACKGROUND Angiogenesis is involved in the pathogenesis of arthritis. OBJECTIVE The aim of the study was to assess the serum levels of selected angiogenic cytokines and their association with clinical presentation in patients with psoriatic arthritis (PsA) and SAPHO syndrome. METHODS We studied 98 patients: 80 with PsA and 18 with SAPHO syndrome. The following data were recorded: age, sex, disease duration, joint involvement, type of psoriasis, nail involvement, and treatment. The following indices used to assess the activity of PsA and SAPHO were measured: PASI, BASDAI, BASFI, BASMI, BASG, and VAS pain. We determined erythrocyte sedimentation rate, C‑reactive protein (CRP), and platelet count. The serum levels of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic and acidic fibroblast growth factors (FGFb and FGFa) were determined using an enzyme‑linked immunosorbent assay. RESULTS In patients with PsA, VEGF levels were positively correlated with CRP (P = 0.04), BASFI (P = 0.03), and disease duration (P = 0.007). No differences were found between patients with and without nail psoriasis in the VEGF or EGF levels (P = 0.32 and P = 0.85, respectively). There were no differences between patients with the peripheral and axial forms of arthritis in VEGF or EGF levels (P = 0.56 and P = 0.28, respectively). No significant correlations were observed between EGF and FGF levels and clinical presentation in patients with PsA. In patients with SAPHO, no significant correlations were found between angiogenic cytokine levels and clinical presentation. CONCLUSIONS Our data suggest a role of VEGF in the pathogenesis of PsA. Further studies are required to better understand the role of angiogenic cytokines in PsA.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015535 Arthritis, Psoriatic A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor. Psoriasis Arthropathica,Psoriasis, Arthritic,Psoriatic Arthritis,Psoriatic Arthropathy,Arthritic Psoriasis,Arthropathies, Psoriatic,Arthropathy, Psoriatic,Psoriatic Arthropathies
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D016220 Fibroblast Growth Factor 1 A 17-kDa single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. It binds to HEPARIN, which potentiates its biological activity and protects it from proteolysis. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages, and also has chemotactic and mitogenic activities. It was originally named acidic fibroblast growth factor based upon its chemical properties and to distinguish it from basic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 2). Acidic Fibroblast Growth Factor,Class I Heparin-Binding Growth Factor,Fibroblast Growth Factor, Acidic,HBGF-1,Heparin-Binding Fibroblast Growth Factor Class I,Heparin-Binding Growth Factor, Class I,FGF-1,FGF1,Fibroblast Growth Factor-1,Heparin Binding Growth Factor, Class I

Related Publications

Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
May 1999, Rheumatology (Oxford, England),
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
January 1985, Scandinavian journal of rheumatology,
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
June 1977, Annals of the rheumatic diseases,
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
December 2004, Cancer letters,
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
January 2013, Disease markers,
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
January 2013, ISRN dermatology,
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
April 1995, Revista clinica espanola,
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
September 2021, Journal of reproductive immunology,
Hanna Przepiera-Będzak, and Katarzyna Fischer, and Marek Brzosko
January 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
Copied contents to your clipboard!